Stock Track | GRAIL, Inc. Surges 16.73% After-Hours on Positive Outlook

Stock Track02-20

GRAIL, Inc. (GRAL) saw its stock soar 16.73% in after-hours trading on Thursday, following an optimistic outlook from analysts on the company's prospects in the cancer screening and early detection market.

According to the news article titled "This isn't a 10-stock show right now. Here's where to find opportunities with the S&P 500 at all-time highs," trader Simon Ree highlighted GRAIL as a top holding in the Innovator IB 50 fund (FFTY), an ETF that focuses on companies with strong profit growth, high margins, and high return on equity. The article noted that GRAIL's Apollo Go robotaxi is expected to break even in Wuhan in 2024 and be profitable in 2025 as the company expands its fleet in the city.

Analysts have been bullish on GRAIL's potential in the liquid biopsy market, which aims to detect cancer early through a simple blood test. The company's Galleri multi-cancer early detection test has shown promising results in clinical trials, and its recent partnership with leading healthcare providers has fueled expectations for widespread adoption and revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118653570?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-21 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118653570","market":"hk","top_or_hot":-1,"title":"Stock Track | GRAIL, Inc. Surges 16.73% After-Hours on Positive Outlook","media":"Stock Track","content":"<p>GRAIL, Inc. (GRAL) saw its stock soar 16.73% in after-hours trading on Thursday, following an optimistic outlook from analysts on the company's prospects in the cancer screening and early detection market.</p>\n\n<p>According to the news article titled \"This isn't a 10-stock show right now. Here's where to find opportunities with the S&P 500 at all-time highs,\" trader Simon Ree highlighted GRAIL as a top holding in the Innovator IB 50 fund (FFTY), an ETF that focuses on companies with strong profit growth, high margins, and high return on equity. The article noted that GRAIL's Apollo Go robotaxi is expected to break even in Wuhan in 2024 and be profitable in 2025 as the company expands its fleet in the city.</p>\n\n<p>Analysts have been bullish on GRAIL's potential in the liquid biopsy market, which aims to detect cancer early through a simple blood test. The company's Galleri multi-cancer early detection test has shown promising results in clinical trials, and its recent partnership with leading healthcare providers has fueled expectations for widespread adoption and revenue growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GRAIL, Inc. Surges 16.73% After-Hours on Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GRAIL, Inc. Surges 16.73% After-Hours on Positive Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-21 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GRAIL, Inc. (GRAL) saw its stock soar 16.73% in after-hours trading on Thursday, following an optimistic outlook from analysts on the company's prospects in the cancer screening and early detection market.</p>\n\n<p>According to the news article titled \"This isn't a 10-stock show right now. Here's where to find opportunities with the S&P 500 at all-time highs,\" trader Simon Ree highlighted GRAIL as a top holding in the Innovator IB 50 fund (FFTY), an ETF that focuses on companies with strong profit growth, high margins, and high return on equity. The article noted that GRAIL's Apollo Go robotaxi is expected to break even in Wuhan in 2024 and be profitable in 2025 as the company expands its fleet in the city.</p>\n\n<p>Analysts have been bullish on GRAIL's potential in the liquid biopsy market, which aims to detect cancer early through a simple blood test. The company's Galleri multi-cancer early detection test has shown promising results in clinical trials, and its recent partnership with leading healthcare providers has fueled expectations for widespread adoption and revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"","article_id":"1118653570","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118653570","pubTimestamp":1740087155,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GRAIL, Inc.  saw its stock soar 16.73% in after-hours trading on Thursday, following an optimistic outlook from analysts on the company's prospects in the cancer screening and early detection market.According to the news article titled \"This isn't a 10-stock show right now. Here's where to find opportunities with the S&P 500 at all-time highs,\" trader Simon Ree highlighted GRAIL as a top holding in the Innovator IB 50 fund , an ETF that focuses on companies with strong profit growth, high margin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc."},"translate_title":"由于前景乐观，GRAIL，Inc.盘后股价飙升16.73%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1},"content_text":"GRAIL, Inc. (GRAL) saw its stock soar 16.73% in after-hours trading on Thursday, following an optimistic outlook from analysts on the company's prospects in the cancer screening and early detection market.\nAccording to the news article titled \"This isn't a 10-stock show right now. Here's where to find opportunities with the S&P 500 at all-time highs,\" trader Simon Ree highlighted GRAIL as a top holding in the Innovator IB 50 fund (FFTY), an ETF that focuses on companies with strong profit growth, high margins, and high return on equity. The article noted that GRAIL's Apollo Go robotaxi is expected to break even in Wuhan in 2024 and be profitable in 2025 as the company expands its fleet in the city.\nAnalysts have been bullish on GRAIL's potential in the liquid biopsy market, which aims to detect cancer early through a simple blood test. The company's Galleri multi-cancer early detection test has shown promising results in clinical trials, and its recent partnership with leading healthcare providers has fueled expectations for widespread adoption and revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118653570"}